Abstract:Background Liver sinosoidal endothelial cells (LSECs) are critical gatekeepers of sinusoidal homeostasis. They are the first impaired cells in response to liver injury and contribute to liver fibrosis. Our preliminary studies have shown that hepatic cyclooxygenase-2 (COX-2) expression was correlated with the severity of inflammation and fibrosis. The present study aimed to investigate the role of COX-2 on LSECs function and its underlying molecular mechanism. Methods Liver fibrosis was induced by intraperitoneal injection of thioacetamide (TAA) or feeding 0.1% 3,5-diethoxycarbonyl-1,4-dihydro-collidine (DDC)-containing diet. Mice with LSEC-specific deletion of Ptgs2 or treatment with the COX-2 inhibitors were studied in TAA and/or DDC diet-induced liver fibrosis model. The fibrosis severity, hepatic injury and inflammatory cell infiltration were evaluated. Primary human and murine LSECs were treated with TNFα, or pretreated with different reagents before stimulation. Cell response and target molecule were studied. Results In both acute and chronic liver injury models, COX-2 expression was elevated and was co-stained with LYVE1, an LSEC-specific maker. In in vivo studies, LSEC-specific Ptgs2 deletion reduced liver fibrosis and hepatic inflammation. The down-regulated DEGs by Ptgs2 knockout were enriched in leukocyte chemotaxis, migration and adhesion. In in vitro studies, TNFα activated NF-κB signaling pathway and induced chemokines (CXCL1 and CCL2) and adhesion molecules (ICAM1 and VCAM1). These TNFα-induced effects could be potently suppressed by COX-2-PGE2-EP2 axis inhibitors. The pharmacologic effects of COX-2 were demonstrated by using specific inhibitors. Celecoxib and Etoricoxib, both are selective COX-2 inhibitors, were able to reduce hepatic fibrosis and inflammation. Conclusions COX-2 expression in LSECs is up-regulated in liver fibrosis. Upon inflammatory stimulation, COX-2-PGE2-EP2 axis increases chemokines and adhesion molecules through the synergistic activation of NF-κB signaling pathway, leading to leukocyte recruitment and hepatic inflammation. Inhibition of COX-2 attenuates fibrosis and liver injury. The present study sheds light on the regulation of LSECs on leukocyte recruitment through a cyclooxygenase-2-dependent mechanism. Our results suggest COX-2 as a potential therapeutic target in the treatment of liver fibrosis.

Inhibition of the expression of α-smooth muscle actin in human hepatic stellate cell line, LI90, by a selective cyclooxygenase 2 inhibitor, NS-398

Synthesis and Anti-Hepaticfibrosis of Glycyrrhetinic Acid Derivatives with Inhibiting COX-2

Effect of prostaglandin E2 and prostaglandin I2 on PDGF-induced proliferation of LI90, a human hepatic stellate cell line

NS-398, a Selective Cyclooxygenase 2 Inhibitor, Inhibited Cell Growth and Induced Cell Cycle Arrest in Human Hepatocellular Carcinoma Cell Lines.

Celecoxib Derivative OSU-03012 Inhibits the Proliferation and Activation of Hepatic Stellate Cells by Inducing Cell Senescence.

The Significance of COX-2 and COX-2 Inhibitors in Liver Fibrosis and Liver Cancer

STUDY ON THE EXPRESSION OF CYCLOOXYGENASE-2 IN HEPATOCELLULAR CARCINOMA CELL LINES AND ON THE GROWTH INHIBITION EFFECT OF NS-398

IDDF2024-ABS-0051 Liver Sinosoidal Endothelial Cell Contributes to Leukocyte Recruitment in Liver Fibrosis Through a Cyclooxygenase-2-dependent Mechanism

A Novel Synthetic Oleanolic Acid Derivative (Cpu-Ii2) Attenuates Liver Fibrosis in Mice Through Regulating the Function of Hepatic Stellate Cells

Celecoxib-mediated Attenuation of Non-Alcoholic Steatohepatitis is Potentially Relevant to Redistributing the Expression of Adiponectin Receptors in Rats.

Inonotsuoxide B Suppresses Hepatic Stellate Cell Activation and Proliferation Via the PI3K/AKT and ERK1/2 Pathway

SNS-032 attenuates liver fibrosis by anti-active hepatic stellate cells via inhibition of cyclin dependent kinase 9

Involvement of TLR4 signaling regulated-COX2/PGE2 axis in liver fibrosis induced by Schistosoma japonicum infection

Chemoprevention of Spontaneous Development of Hepatocellular Carcinomas in Fatty Liver Shionogi Mice by a Cyclooxygenase‐2 Inhibitor

Specific COX-2 Inhibitor NS398 Induces Apoptosis in Human Liver Cancer Cell Line HepG2 Through BCL-2

Suberoylanilide hydroxamic acid suppresses hepatic stellate cells activation by HMGB1 dependent reduction of NF-κB1.

Effect of Cyclooxygenase-2 on Liver Fibrogenesis Induced by CCl4 in Rats

Expression of Cyclooxygenase 2 and Cytosolic Phospholipase A(2) in the Liver Tissue of Patients with Chronic Hepatitis and Liver Cirrhosis.

Cyclooxygenase-2 Prevents Fas-Induced Liver Injury Through Up-Regulation of Epidermal Growth Factor Receptor

Effects of NS398, an inhibitor of cyclooxygenase 2, on the growth and apoptosis of human squamous cell carcinoma cell line Tca8113

Enhanced Effects of Novel Oridonin Analog Cyd0682 for Hepatic Fibrosis